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1. Introduction 
Our recent study [ 1 ] on synthetic analogs of 
enkephalins (Tyr-Gly-Gly-Phe-X, X = Met and 
Leu [2] ) has revealed some structural requirements 
for a pentapeptide to exert antinociceptive property 
by intravenous application. First, Gly* has been 
replaced by a D-amino acid, the side-chain of which 
has been supposed to provide an extra binding-site 
for the receptor [l ] . To support his view the 
D-Met*’ analog was more active both in vitro and in 
vivo than the D-Ala* and even the D-Nle* ones [ I] . 
Based on other considerations the replacement of
Gly* by different D-amino acids has also been accom- 
plished by other workers [3-51. To protect the 
fourth peptide bond of enkephalins, i.e., Phe4-x5, 
against proteolysis Met/I_eu’ has been replaced by 
Pro, resulting in a further increase of the in vivo 
biological activity [ 1 ] . Finally, an alkyl amide group 
has been introduced into the COOH-terminus of the 
molecule with the purpose that it should furnish a 
further receptor binding-site. Ethyl amide appeared 
to be superior to amyl amide indicating the size of 
the alkyl amide-group to be crucial. As the most 
significant result of the above attempts, ethyl amide 
of (D-Met’, Pro’)-enkephalin has been reported to 
have 55% of the analgesic activity of morphine by 
intravenous injection [ I] . 
In this paper we report the synthesis of an even 
more potent analgesic: (D-Met*, Pro’)-enkephalinamide. 
Table 1 
Relative antinociceptive potency of p-endorphin, Mets-enkephalin and Pro’- 
enkephalinamide analogs by the tail-flick test in rat 
Compound Potency ratio 
on a molar basis 
(morphine = 1) 
&Endorphin 
H-Tyr- Gly-Gly-Phe-Met-OH 
H-D- Ala- Pro-NH-Amy1 
H-D- Al- Pro-NH-Et 
H-D- Ala- Pro-NH, 
H-D- Met- Pro-NH-Et 
H-Tyr-D-Met-Gly-Phe-Pro-NH, 
Intravenously Centrally 
19.3a 
3-4b 21.8c 
Od 0.02d 
O.ld 0.08d 
0.19d 16.gd 
0.22 3.9 
0.55d 16.gd 
5.5 49.8 
a Ref. [8,9] 
b#c Determined by the tail-flick test in mice [ 1 l] and in rat [ 101, respectively 
d Ref. [l] 
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2. Experimental References 
Starting from free proline, Boc-Tyr-D-Met-Gly- 
Phe-Pro-OH was prepared by the stepwise method 
in solution. The N-protected peptide amide was 
obtained by dicyclohexylcarbodiimide-condensation 
of the peptide acid and ammonia which was added 
as its 1-hydroxybenzotriazole (HOBO salt. Deblock- 
ing gave Tyr-D-Met-Gly-Phe-Pro-NH* (thin-layer 
chromatography: RF 0.55 in a mixture of ethyl 
acetatelpyridinelacetic acid/water, 60: 20: 6: 11). 
Amino acid analysis after acid hydrolysis howed the 
expected composition. Details of the synthesis of this 
compound and its analogs (some of the latter are also 
shown in table 1) were described elsewhere [6]. The 
new reagent for amidation, NHs.HOBt, was obtained 
by dissolving HOBt in aqueous ammonia followed by 
dilution with acetone, melting point 184- 185’C with 
darkening at 162°C. 
Antinociceptive properties were examined by the 
tail-flick test in rat [7] as described previously [I] . 
3. Results 
Data of table 1 show that (D-Met’, Pro’)enke- 
phalinamide is5.5~times more potent than morphine 
when injected intravenously and 49.8-times more 
active than inorphine when applied centrally. Thus 
for the first time an analgesic of peptide nature has 
been prepared which is more active than /3-endorphin 
itself [8-l 11. 
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